Anti-Inflammatory Drug
Sep 24, 2026
Powerful Medical’s AI ECG Technology Earns FDA De Novo Authorization for Heart Attack Detection; Werfen Secures US FDA 510(k) Clearance and CE Mark for Aptiva® APS IgA Reagent; Ontario Introduces Fetal Blood Type Screening to Improve Pregnancy Care; Medvue Concorde Acquires Next-Generation AI-Powered MRI System; Cardiol Therapeutics Hits Phase III MAVERIC Enrollment Target Early and Expands Pivotal Trial for CardiolRx; Ferronova Reports Preliminary MAGMAP Results in 62-Patient Gastric and Oesophageal Cancer Trial
Powerful Medical Receives FDA De Novo Authorization for AI-Based ECG Model for Acute Heart Attack Detection On 15 September 2026, Powerful Medical announced that the U.S. Food and Drug Administration had granted De Novo authorization for its Queen of Hearts ACS AI ECG Model. The AI-powered technology was d...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
